AorTech sales drop in half yearly report

Polymer company AorTech posted a drop in sales in its half yearly report, primarily as a result of a lawsuit and development costs.

Polymer company AorTech posted a drop in sales in its half yearly report, primarily as a result of a lawsuit and development costs.

The medical supplies company achieved sales of $822,000 for the six months ended September, of which $724,000 was the sale of polymer to customers, compared to last year's revenue of $2.63m.

Last year's sales were boosted following a renegotiated licence deal with St Jude medical centre.

However, the deal went sour on October 9th, after AorTech served St Jude a lawsuit claiming breach of contract.

St Jude denied the allegations and subsequently filed papers in the US courts seeking a declaratory judgement saying they were not in breach. They were granted a temporary restraining order in November, preventing AorTech from terminating the contract at issue.

AorTech continued to supply materials to St Jude and the cash position was looking critical by the end of October. The company had to gain support from investors, including existing shareholders, to finance the company and the costs of the impending litigation.

The dispute was resolved on Monday, but neither party has admitted liability.

The costs of the lawsuit contributed to the company's lower revenues in the six month period.

The figure also reflected the total deduction of $1.51m incurred by the costs of polymer manufacture, development expenditure, amortisation of intangible assets and administration.

The company said it started the financial period with cash of $1.91m but losses and currency movements between the sterling and the dollar led to a closing cash balance of $295,000.

AorTech was also affected by a sale that fell through for the acquisition of its polymer business.

"The sale process was unsatisfactory due in the main to the difficult time frame that was imposed as a result of the dwindling cash position," the company said in a statement.

Funding was needed to bridge the timescale anticipated to a sale of the polymer business. AorTech concluded that the issue of loan notes was the only option for providing sufficient funds to the company and to protect the interests of shareholders.

Shares fell 4.40% to 87.00p at 11:40 Thursday.

RD

Recommended

Director dealings w/e 5 August: what company insiders are buying and selling
Stocks and shares

Director dealings w/e 5 August: what company insiders are buying and selling

Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company di…
9 Aug 2022
Britain’s most-bought shares w/e 5 August
Stocks and shares

Britain’s most-bought shares w/e 5 August

A look at Britain’s most-bought shares in the week ending 5 August, providing an insight into how investors are thinking and where opportunities may l…
9 Aug 2022
Where to find inflation-resistant stocks
Investment strategy

Where to find inflation-resistant stocks

Terry Smith’s latest update contains some valuable pointers for investors looking to protect against inflation.
8 Aug 2022
A low-risk way to beat inflation
Share tips

A low-risk way to beat inflation

Demand for care-home places is strong and the sector should be able to raise prices ahead of costs, says Max King.
8 Aug 2022

Most Popular

Are UK house prices finally heading for a crash?
House prices

Are UK house prices finally heading for a crash?

The latest house price figures show a fall of 0.1% in July. With interest rates rising, inflation hitting double figures and a recession on the cards,…
5 Aug 2022
Brace yourself for the return of rationing
Economy

Brace yourself for the return of rationing

Russia is turning off the cheap energy. That is already leading to belt-tightening, says Matthew Lynn. Who will suffer most, and which sectors will th…
5 Aug 2022
Fear of missing out – what should investors do now?
Investment strategy

Fear of missing out – what should investors do now?

Markets have rallied from their mid-June lows. But if you missed out, as most investors did, what should you do now? Max King explains.
8 Aug 2022